4,470 Shares in Astrazeneca Plc $AZN Acquired by Arwa LLC

Arwa LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,470 shares of the company’s stock, valued at approximately $784,000.

A number of other institutional investors and hedge funds have also bought and sold shares of AZN. Triumph Capital Management purchased a new stake in shares of Astrazeneca in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in shares of Astrazeneca during the fourth quarter valued at $26,000. Bangor Savings Bank raised its holdings in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca in the fourth quarter valued at about $30,000. Finally, YANKCOM Partnership purchased a new stake in Astrazeneca in the fourth quarter worth about $31,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Trading Down 0.0%

Shares of Astrazeneca stock opened at $174.87 on Friday. The firm’s 50 day simple moving average is $186.62 and its two-hundred day simple moving average is $186.27. The firm has a market capitalization of $271.20 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Analysts predict that Astrazeneca Plc will post 9.39 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on AZN. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Finally, Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.